Quanome Technologies, Inc. (LSH) Form 8-K — Nov 9, 2026
$LSHForm 8-KItems 1.01, 3.02, 7.01, 9.01Filed Nov 9, 2026, 8:01 AM ET0001213900-26-117226Original filing
Quanome Technologies (Nasdaq: QNME, formerly Lakeside Holding) signed a Stock Purchase Agreement on November 4, 2026 to acquire 31,579 newly issued shares of QAI Labs Ltd., an early-stage AI-driven drug discovery company, representing roughly a 5% stake. Quanome will pay entirely in stock, issuing 6,541,236 new shares — about 15.97% of its post-issuance shares outstanding — for a negotiated value of $5.0 million, implying a ~$100 million valuation for QAI Labs and its NOVA-3 multi-specific antibody discovery platform.
Key figures
- Deal Value Usd
- 5000000
- Shares Offered
- 6541236
- Outside closing date
- December 31, 2026
- Seller shares acquired
- 31579
- Stake in qai labs percent
- approximately 5%
- Dilution percent pre issuance
- approximately 19%
- Dilution percent post issuance
- approximately 15.97%
- Implied qai labs valuation usd
- 100000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.